Alkermes, the biopharmaceutical company behind the schizophrenia treatment Lybalvi, may have a much longer stretch without generic competition than previously expected. RBC Capital Markets said a settlement with Teva Pharmaceuticals pushes copycat versions of Lybalvi back to November 2039, or May 2040 in some cases. That is a significant shift from the bank's earlier assumption that generics would arrive in 2032.
The news gives Alkermes a longer runway for Lybalvi sales, which RBC now models peaking at $722 million, up from a prior estimate of $213 million. The settlement essentially removes the so-called "patent cliff" that loomed in the early 2030s, protecting the drug's branded sales for years longer.
What the Teva settlement means
Generic competition typically hits branded drugs hard. Once a lower-priced copy enters the market, the original drug tends to lose both volume and pricing power, often rapidly. By pushing the potential generic entry from 2032 to 2039-2040, Alkermes gains more than just extra years of exclusivity. It protects cash flows that are close enough to today to carry more weight in a discounted cash flow (DCF) model, which values future earnings in today's dollars.
RBC's revised outlook reflects this. The bank now sees Lybalvi's branded sales peaking at $722 million, a substantial increase from its earlier $213 million peak estimate. That revision helps explain why RBC can keep its outperform rating and $57 price target on Alkermes shares, even as it trims expectations for another pipeline drug.
Alixorexton forecasts trimmed
At the same time, RBC lowered its expectations for alixorexton, Alkermes' insomnia-drug candidate. The adjustment came after Takeda Pharmaceutical, a Japanese drugmaker, set list pricing for a rival orexin drug at $16,500 per month across doses, or about $198,000 per year. RBC now assumes alixorexton pricing of roughly $288,000 a year, down from $350,000, and cuts its 2035 sales forecast to $2.7 billion from $3.3 billion.
Orexin drugs are a newer class of insomnia treatments that target a different pathway than older sleep aids. The pricing of Takeda's rival product gives investors a benchmark for what the market might bear, and RBC's revised assumptions reflect a more conservative view on alixorexton's commercial potential.
Even with that haircut, RBC kept its outperform rating and $57 price target, versus shares around $46.67 at the time of its note. The message: the near-term Lybalvi runway matters more to the valuation than some far-off upside from a pipeline program.
What it means for investors
For investors, the key takeaway is that Alkermes' equity story now hinges more on Lybalvi's growth and durability. The Teva settlement removes a major overhang, but it also concentrates the debate: execution on Lybalvi's commercial performance will do more of the heavy lifting for the stock.
RBC's $57 target leans more on Lybalvi with Teva blocked until November 2039. The longer exclusivity period reduces the risk of a sudden revenue drop, which can be a major concern for drugmakers when patents expire. For a company like Alkermes, which has a relatively concentrated product portfolio, the difference between a 2032 and a 2039 generic entry is substantial.
Investors should also note the broader context. The pharmaceutical sector often sees patent cliffs as key events that can reshape a company's financial profile. A delay in generic competition can provide a multi-year buffer, allowing a company to invest in other pipeline programs or return capital to shareholders.
However, the alixorexton pricing cut is a reminder that pipeline optimism can be tempered by competitive realities. While the drug's potential remains, RBC's revised forecasts suggest a more cautious view on its market opportunity.
For now, the market's focus is likely to remain on Lybalvi's sales trajectory and the company's ability to execute on its commercial strategy. The Teva settlement gives Alkermes more time, but it also raises the stakes for delivering on the drug's potential.
